Vor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 70,763 Shares of Stock

Vor Biopharma Inc. (NASDAQ:VOR) major shareholder Reprogrammed Interchange Llc sold 70,763 shares of the stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $37.01, for a total transaction of $2,618,938.63. Following the transaction, the insider owned 1,526,545 shares of the company’s stock, valued at approximately $56,497,430.45. The trade was a 4.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The shares were sold at an average price of $33.84, for a total transaction of $934,796.16.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The stock was sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total transaction of $924,195.80.

Vor Biopharma Price Performance

Shares of NASDAQ:VOR opened at $33.40 on Thursday. The company has a market capitalization of $228.79 million, a price-to-earnings ratio of -0.12 and a beta of 2.07. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80. The stock’s 50-day simple moving average is $38.14.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Vor Biopharma to a “strong sell” rating in a report on Saturday, June 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday. Zacks Research raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 10th. Stifel Nicolaus raised shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Wednesday, September 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Vor Biopharma in a report on Thursday, August 14th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $113.83.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of VOR. Money Concepts Capital Corp raised its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after purchasing an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd purchased a new stake in Vor Biopharma in the second quarter valued at approximately $66,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma in the first quarter valued at approximately $100,000. Finally, Jane Street Group LLC purchased a new stake in Vor Biopharma in the first quarter valued at approximately $140,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.